Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp3 values and favorable drug-like properties

Xiangyi Jiang,Boshi Huang,Fisayo A Olotu,Jing Li,Dongwei Kang,Zhao Wang,Erik De Clercq,Mahmoud E S Soliman,Christophe Pannecouque,Xinyong Liu,Peng Zhan,Fisayo A. Olotu,Mahmoud E.S. Soliman
DOI: https://doi.org/10.1016/j.ejmech.2020.113051
IF: 7.088
2021-03-01
European Journal of Medicinal Chemistry
Abstract:<p>To yield potent HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with favorable drug-like properties, a series of novel diarylpyrimidine derivatives targeting the tolerant region I of the NNRTI binding pocket were designed, synthesized and biologically evaluated. The most active inhibitor <strong>10c</strong> exhibited outstanding antiviral activity against most of the viral panel, being about 2-fold (wild-type, EC<sub>50</sub> = 0.0021 μM), 1.7-fold (K103N, EC<sub>50</sub> = 0.0019 μM), and slightly more potent (E138K, EC<sub>50</sub> = 0.0075 μM) than the NNRTI drug etravirine (ETR). Additionally, <strong>10c</strong> was endowed with relatively low cytotoxicity (CC<sub>50</sub> = 18.52 μM). More importantly, <strong>10c</strong> possessed improved drug-like properties compared to those of ETR with an increased Fsp<sup>3</sup> (Fraction of sp<sup>3</sup> carbon atoms) value. Furthermore, the molecular dynamics simulation and molecular docking studies were implemented to reveal the binding mode of <strong>10c</strong> in the binding pocket. Taken together, <strong>10c</strong> is a promising lead compound that is worth further investigation.</p>
chemistry, medicinal
What problem does this paper attempt to address?